Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings, comprehensive cognitive assessments, neuroimaging and DNA (copy number variant) analyses (in families and patients who agree), and follow-up of course of illness, cognitive status and treatment response to specific antipsychotic drugs. The goal of the study is to test a prior hypothesis about clinical subgroups in this population and to test whether these subgroups predict antipsychotic medication response.
This study relates to the organization of a collection of clinical, biological / genetic and radiological (MRI) data from people with a psychotic episode and from their families. These data will be analyzed to clarify whether there is a different response to antipsychotic treatment based on developmental and clinical expression.To answer the question asked in the research, it is planned to include people with at least one psychotic episode,The target population will be a prospective cohort of patients admitted to a hospital or psychiatric clinic for the treatment of psychotic symptoms.Comprehensive medical evaluation will be carried out according to the clinical features and medical history of each patient, to identify medical causes of psychosis. Comprehensive neuropsychological and speech / language evaluation will be completed. A child psychiatrist-diagnostician will complete the Lifetime Dimensions of Psychosis Scale - Child and Adolescent version at baseline. When the patient and parents agree, structural and functional MRI examinations will also be completed, and blood will be drawn for DNA extraction and analysis. Selected assessments (including evaluation of treatment response to specific antipsychotic drugs) will be performed at follow-up visits after 1, 3 and 5 years.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
200
Selected assessments, including evaluation of treatment response to specific antipsychotic drugs, will be performed at follow-up visits after 1, 3 and 5 years
Fondation Vallée, Gentilly
Gentilly, France
NOT_YET_RECRUITINGCHRU de Lille
Lille, France
NOT_YET_RECRUITINGCHU de Nice
Nice, France
NOT_YET_RECRUITINGPitié Salpétrière
Paris, France
RECRUITINGCHU de Rouen
Rouen, France
NOT_YET_RECRUITINGCHU de Rouvray
Rouen, France
NOT_YET_RECRUITINGLifetime Dimensions of Psychosis Scale-Child and Adolescent Version
Symptoms are rated for lifetime duration and for severity during the worst two-week period. Number of participants assigned to each of four clinical clusters derived by cluster analysis from clinical and developmental ratings on this scale as previously described.
Time frame: 4 months
Clinical global impressions scale - change version
score on a 7 point scale ; worse is 7
Time frame: at 5 years
Cortical gray matter volume (Magnetic Resonance Imaging)
Statistical differences among the four clinical clusters in the summary measure of cortical gray matter volume
Time frame: up to 4 months
Stability of clinical profile on Lifetime Dimensions of Psychosis Scale-Child and Adolescent Version
differences among the four clinical clusters over time, comparing the cluster assignment at the time of stabilization to the assignment at the last study visit
Time frame: at 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.